Case Report: Omadacycline in the Treatment of Community‐Acquired Pneumonia in a Child With Multiple Antimicrobial Allergies

Omadacycline, a novel once-daily aminomethylcycline antibiotic agent, demonstrates efficacy against prevalent pathogens responsible for community-acquired pneumonia (CAP) in adults. However, the safety and efficacy of omadacycline in younger children have not yet been established. This case report presents a 4-year-old girl with a mixed infection of CAP who exhibited hypersensitivity to multiple antimicrobial agents (piperacillin-tazobactam, ceftazidime, fosfomycin, meropenem, and levofloxacin), was treated with omadacycline followed by doxycycline, and underwent bronchoscopy with bronchoalveolar lavage. The child's condition improved, and no adverse reactions to omadacycline were observed. Potential adverse effects of omadacycline were evaluated, along with its utilization and dosage in children. Omadacycline has the potential to be a viable alternative anti-infective agent for the treatment of pediatric CAP in the absence of other drug options and with adequate safety evaluation and monitoring.